Page 63 - Read Online

Le et al. J Transl Genet Genom 2018;2:17. I https://doi.org/10.20517/jtgg.2018.28 Page 9 of 9

55. Nishikawa H, Wu W, Koike A, Kojima R, Gomi H, et al. BRCA1-associated protein 1 interferes with BRCA1/BARD1 RING heterodimer
activity. Cancer Res 2009;69:111-9.
56. Mallery DL, Vandenberg CJ, Hiom K. Activation of the E3 ligase function of the BRCA1/BARD1 complex by polyubiquitin chains. EMBO
J 2002;21:6755-62.
57. Piva F, Santoni M, Matrana MR, Satti S, Giulietti M, et al. BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular
diagnostics and possible targets for personalized therapies. Expert Rev Mol Diagn 2015;15:1201-10.
58. Wang SS, Gu YF, Wolff N, Stefanius K, Christie A, et al. Bap1 is essential for kidney function and cooperates with VHL in renal
tumorigenesis. Proc Natl Acad Sci USA 2014;111:16538-43.
59. Choueiri TK, Escudier B, Powles T, Tannir NM, Mainwaring PN, et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma.
N Engl J Med 2015;373:1814-23.
60. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, et al. Sorafenib in advanced clear cell renal cell carcinoma. N Engl J Med
2007;357:203.
61. Motzer RJ, Hutson TE, Glen H, Michaelson MD, Molina A, et al. Lenvatinib, everolimus, and the combination in patients with metastatic
renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol 2015;16:1473-82.
62. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, et al. Sunitinb versus interferon alfa in metastatic renal cell carcinoma.
N Engl J Med 2007;356:115-24.
63. Motzer RJ, McCann L, Deen K. Pazopanib versus sunitinib in renal cancer. N Engl J Med 2013;369:1970.
64. Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell
carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011;378:1931-9.
65. Escudier B, PLuzanska A, Koralewski P, Ravaud A, Bracarda S, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal
cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370:2103-11.
66. Hudes G, Carducci M, Tomczak P. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med
2007;356:2271-81.
67. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind,
randomised, placebo-controlled phase III trial. Lancet 2008;372:449-56.
68. McDermott DF, Regan MM, Clark JI, Flaherty LE, Weiss GR, et al. Randomized phase III trial of high-dose interleukin-2 versus
subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005;23:133-41.
69. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N
Engl J Med 2015;373:1803-13.
70. Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal
cell carcinoma. N Engl J Med 2018;378:1277-90.